MELAS Spectrum Disorders and Sonlicromanol: Progress Update

March 18, 2022 00:52:51
MELAS Spectrum Disorders and Sonlicromanol: Progress Update
MitoAction Expert Series
MELAS Spectrum Disorders and Sonlicromanol: Progress Update

Mar 18 2022 | 00:52:51

/

Show Notes

Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary mitochondrial diseases with an unmet medical need for treatment development. Following an introduction of the clinical disease spectrum Dr. Smeitink will discuss the development and state-of-art of Khondrion’s lead product sonlicromanol.

Other Episodes

Episode

September 03, 2026 00:55:59
Episode Cover

Understanding the potential of a “CPK Meter”

IVDS is a biotech company developing a CPK meter called, CPK Now. This small, handheld device will allow patients to check their creatine kinase...

Listen

Episode

May 19, 2022 01:03:14
Episode Cover

Introducing Bendavia

Join us with Dr. Ben Bronstein and Travis Wilson from Stealth Peptides. Stealth Peptides is a private biotech company responsible for the development of...

Listen

Episode

March 08, 2025 01:22:27
Episode Cover

Expert Series: Ins and Outs of the Mito Cocktail: Pat 1 of 2

In the, “Ins and Outs of the Mito Cocktail: Part 1 of 2,” Dr. Toufas will explore how our bodies digest and absorb nutrients...

Listen